Invitae is a genetic information company and has raised a total of $207 million from investors to date. It provides a single diagnostic test comprising over 200 genes for $1,500. Decheng Capital, based in Shanghai, provides capital to early and growth stage life science companies and already has stakes in other firms like GeneWeave, GenapSys, SentreHeart, 3SBio, Shenzhen GeneMDx Biotech and SINO Medical Sciences.
To see listing and email addresses of investors from China similar to Decheng Capital, check the Chinese Investors Directory
More details follows
Previous Post: China's Anbang acquired Hilton's NY Waldorf for $1.95 billion
Next Post: Chinese investors led $70 million investment in San Francisco education firm Minerva